TN2015000175A1 - Heteroaryl substituted pyridyl compounds useful as kinase modulators - Google Patents
Heteroaryl substituted pyridyl compounds useful as kinase modulatorsInfo
- Publication number
- TN2015000175A1 TN2015000175A1 TNP2015000175A TN2015000175A TN2015000175A1 TN 2015000175 A1 TN2015000175 A1 TN 2015000175A1 TN P2015000175 A TNP2015000175 A TN P2015000175A TN 2015000175 A TN2015000175 A TN 2015000175A TN 2015000175 A1 TN2015000175 A1 TN 2015000175A1
- Authority
- TN
- Tunisia
- Prior art keywords
- compounds useful
- kinase modulators
- heteroaryl substituted
- substituted pyridyl
- pyridyl compounds
- Prior art date
Links
- 108091000080 Phosphotransferase Proteins 0.000 title abstract 2
- 125000001072 heteroaryl group Chemical group 0.000 title abstract 2
- 102000020233 phosphotransferase Human genes 0.000 title abstract 2
- 125000004076 pyridyl group Chemical group 0.000 title 1
- 102100023533 Interleukin-1 receptor-associated kinase 4 Human genes 0.000 abstract 1
- 101710199010 Interleukin-1 receptor-associated kinase 4 Proteins 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 125000002950 monocyclic group Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
- Epidemiology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261723848P | 2012-11-08 | 2012-11-08 | |
| US201361774824P | 2013-03-08 | 2013-03-08 | |
| PCT/US2013/068875 WO2014074675A1 (fr) | 2012-11-08 | 2013-11-07 | Composés pyridyle à substitution hétéroaryle utiles en tant que modulateurs de kinase |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TN2015000175A1 true TN2015000175A1 (en) | 2016-10-03 |
Family
ID=49667571
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TNP2015000175A TN2015000175A1 (en) | 2012-11-08 | 2015-05-07 | Heteroaryl substituted pyridyl compounds useful as kinase modulators |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US9657009B2 (fr) |
| EP (1) | EP2917206B1 (fr) |
| JP (1) | JP6204484B2 (fr) |
| KR (1) | KR20150079963A (fr) |
| CN (1) | CN104781254B (fr) |
| AU (1) | AU2013341200A1 (fr) |
| BR (1) | BR112015009850A2 (fr) |
| CA (1) | CA2890983A1 (fr) |
| CL (1) | CL2015001249A1 (fr) |
| CO (1) | CO7400871A2 (fr) |
| EA (1) | EA024940B1 (fr) |
| ES (1) | ES2615302T3 (fr) |
| HK (1) | HK1213895A1 (fr) |
| IL (1) | IL238609A0 (fr) |
| MX (1) | MX2015005562A (fr) |
| PE (1) | PE20150953A1 (fr) |
| PH (1) | PH12015501005A1 (fr) |
| SG (1) | SG11201503397YA (fr) |
| TN (1) | TN2015000175A1 (fr) |
| TW (1) | TW201427953A (fr) |
| WO (1) | WO2014074675A1 (fr) |
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014074657A1 (fr) | 2012-11-08 | 2014-05-15 | Bristol-Myers Squibb Company | Composés pyridyles à substitution par hétérocycle bicyclique utiles en tant que modulateurs de kinase |
| PE20150953A1 (es) | 2012-11-08 | 2015-06-20 | Bristol Myers Squibb Co | Compuestos de piridilo sustituidos con heteroarilo utiles como moduladores de cinasa |
| NZ709260A (en) | 2012-12-21 | 2016-07-29 | Gilead Sciences Inc | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use |
| NO2865735T3 (fr) | 2013-07-12 | 2018-07-21 | ||
| UY35935A (es) * | 2014-01-03 | 2015-06-30 | Bristol Myers Squibb Company Una Corporación Del Estado De Delaware | Compuestos de nicotinamida sustituida con heteroarilo como inhibidores de quinasa y moduladores de irak-4 |
| TWI677489B (zh) * | 2014-06-20 | 2019-11-21 | 美商基利科學股份有限公司 | 多環型胺甲醯基吡啶酮化合物之合成 |
| TW201613936A (en) | 2014-06-20 | 2016-04-16 | Gilead Sciences Inc | Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide |
| NO2717902T3 (fr) | 2014-06-20 | 2018-06-23 | ||
| CN108026099B (zh) * | 2015-06-24 | 2020-07-10 | 百时美施贵宝公司 | 经杂芳基取代的氨基吡啶化合物 |
| EP3313840B1 (fr) | 2015-06-24 | 2019-07-24 | Bristol-Myers Squibb Company | Composés d'aminopyridine substitués par hétéroaryle |
| KR102641263B1 (ko) | 2015-06-24 | 2024-02-26 | 브리스톨-마이어스 스큅 컴퍼니 | 헤테로아릴 치환된 아미노피리딘 화합물 |
| EA033679B1 (ru) | 2015-09-02 | 2019-11-15 | Glaxosmithkline Ip No 2 Ltd | Пиридинондикарбоксамиды для применения в качестве ингибиторов бромодомена |
| JP6795588B2 (ja) | 2015-09-22 | 2020-12-02 | グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー２）、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ （Ｎｏ．２） Ｌｉｍｉｔｅｄ | ブロモドメイン阻害薬としての使用のためのピリジノンジカルボキサミド |
| ES2831322T3 (es) | 2015-10-05 | 2021-06-08 | Glaxosmithkline Ip No 2 Ltd | Compuestos de 2-oxo-1,2-dihidropiridin-3,5-dicarboxamida como inhibidores de bromodominios |
| KR102097878B1 (ko) * | 2015-11-26 | 2020-04-06 | 노파르티스 아게 | 디아미노 피리딘 유도체 |
| AU2017245641A1 (en) | 2016-04-07 | 2018-09-13 | Glaxosmithkline Intellectual Property (No.2) Limited | Pyridyl derivatives as bromodomain inhibitors |
| CN109153646B (zh) * | 2016-05-24 | 2022-08-02 | 葛兰素史克知识产权第二有限公司 | 作为溴结构域抑制剂的吡啶二甲酰胺衍生物 |
| JOP20180011A1 (ar) | 2017-02-16 | 2019-01-30 | Gilead Sciences Inc | مشتقات بيرولو [1، 2-b]بيريدازين |
| JOP20190192A1 (ar) | 2017-03-01 | 2019-08-08 | Glaxosmithkline Ip No 2 Ltd | مشتقات بيرازول بوصفها مثبطات برومودومين |
| GB201703282D0 (en) | 2017-03-01 | 2017-04-12 | Glaxosmithkline Intellectual Property (No 2) Ltd | Compounds |
| TW201900640A (zh) | 2017-05-11 | 2019-01-01 | 美商必治妥美雅史谷比公司 | 作為irak4抑制劑之噻吩并吡啶及苯并噻吩 |
| JP2020524663A (ja) | 2017-06-21 | 2020-08-20 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | Ｉｒａｋ４調節因子としてのイソインドリノン誘導体 |
| CN111094292A (zh) | 2017-06-21 | 2020-05-01 | 豪夫迈·罗氏有限公司 | 作为IRAK4调节剂的吡唑并[1,5a]嘧啶衍生物 |
| EP3684365A4 (fr) | 2017-09-22 | 2021-09-08 | Kymera Therapeutics, Inc. | Agents de dégradation des protéines et utilisations de ces derniers |
| EP3684366A4 (fr) | 2017-09-22 | 2021-09-08 | Kymera Therapeutics, Inc. | Ligands crbn et utilisations de ces derniers |
| WO2019111218A1 (fr) | 2017-12-08 | 2019-06-13 | Cadila Healthcare Limited | Nouveaux composés hétérocycliques utilisés en tant qu'inhibiteurs d'irak4 |
| IL315310A (en) * | 2017-12-26 | 2024-10-01 | Kymera Therapeutics Inc | Irak degraders and uses thereof |
| EP3737675A4 (fr) | 2018-01-12 | 2022-01-05 | Kymera Therapeutics, Inc. | Ligands crbn et leurs utilisations |
| EP3737666A4 (fr) | 2018-01-12 | 2022-01-05 | Kymera Therapeutics, Inc. | Agents de dégradation de protéines et utilisations associées |
| EP3817822A4 (fr) | 2018-07-06 | 2022-07-27 | Kymera Therapeutics, Inc. | Agents de dégradation de protéines et leurs utilisations |
| WO2020010177A1 (fr) | 2018-07-06 | 2020-01-09 | Kymera Therapeutics, Inc. | Ligands crbn tricycliques et leurs utilisations |
| TWI898556B (zh) | 2018-07-13 | 2025-09-21 | 美商基利科學股份有限公司 | 吡咯并[1,2-b]嗒衍生物 |
| US12187686B2 (en) | 2018-09-07 | 2025-01-07 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | BRD4-JAK2 inhibitors |
| WO2020051572A1 (fr) * | 2018-09-07 | 2020-03-12 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Inhibiteurs de brd4-jak2 |
| SG11202105424PA (en) | 2018-11-30 | 2021-06-29 | Kymera Therapeutics Inc | Irak degraders and uses thereof |
| KR20220035447A (ko) | 2019-07-18 | 2022-03-22 | 브리스톨-마이어스 스큅 컴퍼니 | IRAK4 억제제로서 유용한 피라졸로[3,4-d]피롤로[1,2-b]피리다지닐 화합물 |
| WO2021011724A1 (fr) | 2019-07-18 | 2021-01-21 | Bristol-Myers Squibb Company | Composés hétéroaryle tricycliques utiles en tant qu'inhibiteurs d'irak4 |
| JP7573596B2 (ja) * | 2019-07-23 | 2024-10-25 | ブリストル－マイヤーズ スクイブ カンパニー | Ｉｒａｋ４阻害剤として有用なチエノピリジニルおよびチアゾロピリジニル化合物 |
| US20220380372A1 (en) * | 2019-08-13 | 2022-12-01 | Bristol-Myers Squibb Company | Bicyclic heteroaryl compounds useful as irak4 inhibitors |
| EP4076524A4 (fr) | 2019-12-17 | 2023-11-29 | Kymera Therapeutics, Inc. | Agents de dégradation d'irak et leurs utilisations |
| MX2022007576A (es) | 2019-12-17 | 2022-09-23 | Kymera Therapeutics Inc | Degradadores de cinasas asociadas al receptor de interleucina-1 (irak) y usos de los mismos. |
| WO2021133809A1 (fr) | 2019-12-23 | 2021-07-01 | Blueprint Medicines Corporation | Inhibiteurs de formes mutantes de l'egfr |
| WO2021158495A1 (fr) | 2020-02-03 | 2021-08-12 | Bristol-Myers Squibb Company | Composés de benzo[5,6] [1,4]dioxino[2,3-b]pyridine utiles en tant qu'inhibiteurs de l'irak4 |
| JP7682191B2 (ja) * | 2020-02-03 | 2025-05-23 | ブリストル－マイヤーズ スクイブ カンパニー | Ｉｒａｋ４阻害剤として有用な三環ヘテロアリール化合物 |
| TW202210483A (zh) | 2020-06-03 | 2022-03-16 | 美商凱麥拉醫療公司 | Irak降解劑之結晶型 |
| US20240076285A1 (en) * | 2020-12-16 | 2024-03-07 | Shankar Venkatraman | Compounds and compositions for treating conditions associated with sting activity |
| AU2021413371A1 (en) | 2020-12-30 | 2023-07-13 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| AU2022220043A1 (en) | 2021-02-15 | 2023-08-31 | Kymera Therapeutics, Inc. | Irak4 degraders and uses thereof |
| US12097261B2 (en) | 2021-05-07 | 2024-09-24 | Kymera Therapeutics, Inc. | CDK2 degraders and uses thereof |
| CN118302168A (zh) | 2021-10-29 | 2024-07-05 | 凯麦拉医疗公司 | Irak4降解剂和其制备 |
| WO2023092034A1 (fr) * | 2021-11-17 | 2023-05-25 | Northwestern University | Inhibition de wt-idh1 à l'aide d'un petit inhibiteur moléculaire covalent et pénétrant dans le cerveau pour l'induction de la ferroptose dans un gliome de grade élevé |
| EP4472967A2 (fr) | 2022-01-31 | 2024-12-11 | Kymera Therapeutics, Inc. | Agents de dégradation d'irak et leurs utilisations |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6825190B2 (en) | 2001-06-15 | 2004-11-30 | Vertex Pharmaceuticals Incorporated | Protein kinase inhibitors and uses thereof |
| AUPR688101A0 (en) | 2001-08-08 | 2001-08-30 | Luminis Pty Limited | Protein domains and their ligands |
| GB0211019D0 (en) | 2002-05-14 | 2002-06-26 | Syngenta Ltd | Novel compounds |
| ATE530530T1 (de) | 2002-06-28 | 2011-11-15 | Astellas Pharma Inc | Diaminopyrimidincarbonsäureamidderivat |
| MXPA05007503A (es) | 2003-01-17 | 2005-09-21 | Warner Lambert Co | Heterociclicos 2-aminopiridina sustituidos como inhibidores de proliferacion celular. |
| CN1820001A (zh) | 2003-07-10 | 2006-08-16 | 神经能质公司 | 经取代的杂环二芳基胺类似物 |
| GB0402653D0 (en) | 2004-02-06 | 2004-03-10 | Cyclacel Ltd | Compounds |
| US7521457B2 (en) | 2004-08-20 | 2009-04-21 | Boehringer Ingelheim International Gmbh | Pyrimidines as PLK inhibitors |
| FR2896503B1 (fr) | 2006-01-23 | 2012-07-13 | Aventis Pharma Sa | Nouveaux derives soufres d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases |
| KR20100020454A (ko) | 2007-06-08 | 2010-02-22 | 바이엘 크롭사이언스 소시에떼아노님 | 살진균제 헤테로사이클릴-피리미디닐-아미노 유도체 |
| WO2009046416A1 (fr) | 2007-10-05 | 2009-04-09 | Targegen Inc. | Anilinopyrimidines en tant qu'inhibiteurs de kinases jak |
| GB0719644D0 (en) | 2007-10-05 | 2007-11-14 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
| EP2070924A1 (fr) | 2007-12-10 | 2009-06-17 | Bayer Schering Pharma Aktiengesellschaft | Nouveaux dérivés de 2-hetarylthiazol-4-amides d'acide carboxylique, leur fabrication et leur utilisation en tant que médicament |
| CA2745004C (fr) * | 2008-11-28 | 2014-07-15 | Kowa Company, Ltd. | Derive de pyridine-3-carboxyamide |
| CN102458402B (zh) | 2009-06-12 | 2013-10-02 | 百时美施贵宝公司 | 用作激酶调节剂的烟酰胺化合物 |
| JP5770198B2 (ja) | 2009-10-30 | 2015-08-26 | ヤンセン ファーマシューティカ エヌ．ベー． | オピオイド受容体調節因子としてのフェノキシ置換ピリミジン |
| US20190192510A1 (en) | 2010-02-01 | 2019-06-27 | Nippon Chemiphar Co., Ltd. | Gpr119 agonist |
| CN102834380B (zh) * | 2010-03-10 | 2015-04-01 | 阿斯利康公司 | 蛋白激酶的抑制剂 |
| JP2014515029A (ja) | 2011-04-29 | 2014-06-26 | アイカーン・スクール・オブ・メディシン・アト・マウント・シナイ | キナーゼ阻害剤 |
| WO2013106614A1 (fr) | 2012-01-13 | 2013-07-18 | Bristol-Myers Squibb Company | Composés pyridyles à substitution triazolyle utiles comme inhibiteurs de kinases |
| US9242976B2 (en) | 2012-01-13 | 2016-01-26 | Bristol-Myers Squibb Company | Thiazolyl- or thiadiazolyl-substituted pyridyl compounds useful as kinase inhibitors |
| JP6109195B2 (ja) | 2012-01-13 | 2017-04-05 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | キナーゼ阻害剤として有用な複素環置換されたピリジル化合物 |
| BR112015010244A8 (pt) * | 2012-11-08 | 2019-10-01 | Bristol Myers Squibb Co | compostos de piridila substituída por alquil-amida úteis como moduladores de il-12, il-23 e/ou respostas de ifnalfa, sua composição farmacêutica e seu uso |
| PE20150953A1 (es) | 2012-11-08 | 2015-06-20 | Bristol Myers Squibb Co | Compuestos de piridilo sustituidos con heteroarilo utiles como moduladores de cinasa |
| UY35935A (es) | 2014-01-03 | 2015-06-30 | Bristol Myers Squibb Company Una Corporación Del Estado De Delaware | Compuestos de nicotinamida sustituida con heteroarilo como inhibidores de quinasa y moduladores de irak-4 |
-
2013
- 2013-11-07 PE PE2015000613A patent/PE20150953A1/es not_active Application Discontinuation
- 2013-11-07 AU AU2013341200A patent/AU2013341200A1/en not_active Abandoned
- 2013-11-07 WO PCT/US2013/068875 patent/WO2014074675A1/fr not_active Ceased
- 2013-11-07 HK HK16101951.7A patent/HK1213895A1/zh unknown
- 2013-11-07 CA CA2890983A patent/CA2890983A1/fr not_active Abandoned
- 2013-11-07 TW TW102140575A patent/TW201427953A/zh unknown
- 2013-11-07 JP JP2015541886A patent/JP6204484B2/ja not_active Expired - Fee Related
- 2013-11-07 SG SG11201503397YA patent/SG11201503397YA/en unknown
- 2013-11-07 ES ES13795914.4T patent/ES2615302T3/es active Active
- 2013-11-07 KR KR1020157014808A patent/KR20150079963A/ko not_active Withdrawn
- 2013-11-07 EP EP13795914.4A patent/EP2917206B1/fr not_active Not-in-force
- 2013-11-07 EA EA201590920A patent/EA024940B1/ru not_active IP Right Cessation
- 2013-11-07 BR BR112015009850A patent/BR112015009850A2/pt not_active IP Right Cessation
- 2013-11-07 US US14/441,705 patent/US9657009B2/en active Active
- 2013-11-07 CN CN201380058618.7A patent/CN104781254B/zh not_active Expired - Fee Related
- 2013-11-07 MX MX2015005562A patent/MX2015005562A/es unknown
-
2015
- 2015-05-04 IL IL238609A patent/IL238609A0/en unknown
- 2015-05-06 PH PH12015501005A patent/PH12015501005A1/en unknown
- 2015-05-07 TN TNP2015000175A patent/TN2015000175A1/fr unknown
- 2015-05-08 CL CL2015001249A patent/CL2015001249A1/es unknown
- 2015-06-03 CO CO15127843A patent/CO7400871A2/es unknown
-
2017
- 2017-04-06 US US15/480,682 patent/US10023562B2/en active Active
-
2018
- 2018-06-15 US US16/009,389 patent/US10544133B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EA024940B1 (ru) | 2016-11-30 |
| CN104781254B (zh) | 2016-12-14 |
| EA201590920A1 (ru) | 2015-09-30 |
| CA2890983A1 (fr) | 2014-05-15 |
| HK1213895A1 (zh) | 2016-07-15 |
| PE20150953A1 (es) | 2015-06-20 |
| CN104781254A (zh) | 2015-07-15 |
| JP2016501186A (ja) | 2016-01-18 |
| US20150284382A1 (en) | 2015-10-08 |
| EP2917206B1 (fr) | 2016-12-21 |
| CL2015001249A1 (es) | 2015-07-31 |
| CO7400871A2 (es) | 2015-09-30 |
| ES2615302T3 (es) | 2017-06-06 |
| US10023562B2 (en) | 2018-07-17 |
| US20180370956A1 (en) | 2018-12-27 |
| EP2917206A1 (fr) | 2015-09-16 |
| US20170210730A1 (en) | 2017-07-27 |
| PH12015501005A1 (en) | 2015-07-27 |
| IL238609A0 (en) | 2015-06-30 |
| WO2014074675A1 (fr) | 2014-05-15 |
| KR20150079963A (ko) | 2015-07-08 |
| US9657009B2 (en) | 2017-05-23 |
| BR112015009850A2 (pt) | 2017-07-11 |
| TW201427953A (zh) | 2014-07-16 |
| AU2013341200A1 (en) | 2015-07-02 |
| SG11201503397YA (en) | 2015-05-28 |
| JP6204484B2 (ja) | 2017-09-27 |
| MX2015005562A (es) | 2015-07-23 |
| US10544133B2 (en) | 2020-01-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TN2015000175A1 (en) | Heteroaryl substituted pyridyl compounds useful as kinase modulators | |
| PH12018500342A1 (en) | Heterocyclic amides as kinase inhibitors | |
| PH12015502031A1 (en) | Tetrahydropyrrolothiazine compounds | |
| MX2015002040A (es) | Baricitinib deuterado. | |
| IN2015DN00598A (fr) | ||
| MY171055A (en) | 3,5-disubstituted alkynylbenzene compound and salt thereof | |
| MY194668A (en) | Amide-substituted heterocyclic compounds useful as modulators of il-12, il-23 and/or ifn() responses | |
| MX2016005853A (es) | Compuestos de piridilo sustituidos con alquilamida utiles como muduladores de respuestas de citocinas heterodimericas interleucina 12 y 23 (il-12 e il-23) y/o interferon alfa (ifnalfa). | |
| PH12016500225B1 (en) | Novel quinoline-substituted compound | |
| IN2012DE00621A (fr) | ||
| JO3318B1 (ar) | مثبطات bace | |
| IN2012DE00620A (fr) | ||
| MX2015008829A (es) | Momelotinib deuterado. | |
| EA201591915A1 (ru) | Соединения феноксиэтил дигидро-1h-изохинолина | |
| MX2015016332A (es) | Inhibidores de alk biciclicos fusionados. | |
| EA201892449A1 (ru) | Конденсированные гетероциклические соединения | |
| MX2015007309A (es) | Derivado de hidantoina. | |
| MX2016006807A (es) | Derivados de imidazol. | |
| MX2015012610A (es) | Pacritinib deuterizado. | |
| WO2015044960A3 (fr) | Composés pour l'inhibition de la croissance cellulaire non régulée | |
| IN2012DE00110A (fr) | ||
| UA86566U (en) | N-hydroxyhomoazaadamantanone and dioxomolybdenum complex thereof | |
| MX2018011117A (es) | Forma cristalina. | |
| UA87695U (uk) | Сполука 4,5,6,7-тетрагідро-3н-2-n-(пара-метоксифенациламіно)-азепіну гідрохлорид, що має інотропну активність | |
| IN2013DE03705A (fr) |